An integrated treatment approach in patient with metastatic colorectal cancer and concomitant late cardiovascular complications of chemoradiotherapy for Hodgkin’s lymphoma. Clinical case

The high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular the high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular diseases, remains an urgent problem, the timely diagnosis of which is an important task. the development of a second malignant neoplasm and the appointment of drug antitumor therapy with cardiotoxic agents necessitate a multidisciplinary approach. In the presented clinical observation, such tactics of patient management made it possible not only to timely identify late cardiovascular complications of Hodgkin’s lymphoma chemoradiotherapy, but also to conduct treatment for the second malignant disease with cardiotoxic agents with a positive antitumor effect.

1. Friedman D.L., Constine L.S. Late effects of treatment for Hodgkin lymphoma. J Natl Canc Netw 2006;4(3):249–57. DOI: 10.6004/jnccn.2006.0024

2. Van Leeuwen F.E., Klokman W.J., Veer M.B. et al. Long­-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000;18(3):487–97. DOI: 10.1200/JCO.2000.18.3.487

3. Swerdlow A.J., Barber J.A., Hudson G.V. et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000;18(3):498–509. DOI: 10.1200/JCO.2000.18.3.498

4. Aleman B.M.P., van den Belt­Dusebout A.W., Klokman W.J. et al. Long­-term cause­specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003;21(18):3431–9. DOI: 10.1200/JCO.2003.07.131

5. Meyer R.M., Gospodarowicz M.K., Connors J.M. et al. ABVD alone versus radiation­based therapy in limited­stage Hodgkin’s lymphoma. N Engl J Med 2012;366(5):399–408. DOI: 10.1056/NEJMoa1111961

6. Ng A.K., Bernardo M.P., Weller E. et al. Long­term survival and competing causes of death in patients with early­stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 2002;20(8): 2101–8. DOI: 10.1200/JCO.2002.08.021

7. Hancock S.L., Tucker M.A., Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993;270(16):1949–55.

8. Hoppe R.T. Hodgkin’s disease: complications of therapy and excess mortality. Ann Oncol 1997;8(Suppl. 1):115–8.

9. Potievskaya V.I., Akhobekov A.A., Khmelevsky E.V., Kononova E.V. Radiation­induced ischemic heart disease. Voprosy onkologii = Problems in Oncology 2022;68(2):169–77. (In Russ.).

10. Ilyin N.V., Vinogradova J.N. Late side effects after radio­ and combined therapy in patients with Hodgkin’s disease. Klinicheskaya onkogematologiya = Clinical Oncohematology 2008;1(2):131–5. (In Russ.).

11. Demina E.A. Guidelines for the treatment of Hodgkin’s lymphoma. Moscow: REMEDIUM GROUP, 2018, 72 p. (In Russ.).

12. Biller L.H., Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA 2021;325(7):669–85. DOI: 10.1001/jama.2021.0106

13. – Fedyanin M.Yu., Gladkov O.A., Gordeev S.S. et al. Practical guidelines for drug treatment of colon, rectosigmoid junction, and rectal cancer. Zlokachestvennye opukholi. Prakticheskie rekommehdatsii RUSSCO = Malignant Tumors: RUSSCO Practical Guidelines 2022;12(3s2):401–54. (In Russ.). URL: https://cyberleninka.ru/article/n/prakticheskie-rekomendatsii-po-lekarstvennomu-lecheniyu-raka-obodochnoy-kishki-rektosigmoidnogo-soedineniya-i-pryamoy-kishki?ysclid=lmesyl7in8803436339

14. Becker K., Erckenbrecht J.F., Häussinger D., Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999;57(4):475–84. DOI: 10.2165/00003495-199957040-00003

15. Raber I., Warack S., Kanduri J. et al. Fluoropyrimidine­associated cardiotoxicity: a retrospective case­control study. Oncologist 2020;25(3):e606–9. DOI: 10.1634/theoncologist.2019-0762

16. Polk A., Vaage­Nilsen M., Vistisen K. et al. Cardiotoxicity in cancer patients treated with 5­fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013;39(8):974–84. DOI: 10.1016/j.ctrv.2013.03.005

17. De Forni M., Malet­Martino M.C., Jaillais P. et al. Cardiotoxicity of high­dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992;10(11):1795–801. DOI: 10.1200/JCO.1992.10.11.1795

18. Saif M.W., Shah M.M., Shah A.R. Fluoropyrimidineassociated cardiotoxicity: revisited. Expert Opin Drug Saf 2009;8(2):191–202. DOI: 10.1517/14740330902733961

19. Wang Y., Wang W., Dong H. Risk factors for fluoropyrimidine induced cardiotoxicity in colorectal cancer: a retrospective cohort study and establishment of a prediction nomogram for 5­FU induced cardiotoxicity. Front Oncol 2023;13:1017237. DOI: 10.3389/fonc.2023.1017237

20. Peng J., Dong C., Wang C. et al. Cardiotoxicity of 5­fluorouracil and capecitabine in Chinese patients: a prospective study. Cancer Commun (Lond) 2018;38(1):22. DOI: 10.1186/s40880-018-0292-1

21. Li Y., Tian W., Yue D. et al. Bevacizumab­induced mitochondrial dysfunction, endoplasmic reticulum stress, and ERK inactivation contribute to cardiotoxicity. Oxid Med Cell Longev 2021;2021:5548130. DOI: 10.1155/2021/5548130

22. Puthenpurail A., Rathi H., Nauli S.M., Ally A. A brief synopsis of monoclonal antibody for the treatment of various groups of diseases. World J Pharm Pharm Sci 2021;10(11):14–22.

23. Fornasier G., Francescon S., Baldo P. An update of efficacy and safety of cetuximab in metastatic colorectal cancer: a narrative review. Adv Ther 2018;35(10):1497–509. DOI: 10.1007/s12325-018-0791-0

24. Letsas K.P., Korantzopoulos P., Evangelou D. et al. Acute myocardial infarction with normal coronary arteries in a patient with Hodgkin’s disease: a late complication of irradiation and chemotherapy. Tex Heart Inst J 2006;33(4):512–4.

25. Basavaraju S.R., Easterly C.E. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys 2002;29:2391–403. DOI: 10.1118/1.1509442